PM
CGTX icon

Prosight Management’s Cognition Therapeutics CGTX Stock Holding History

Prosight Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-120,198
Closed -$254K – 39
2022
Q2 		$254K Sell
120,198
-119,882
-50% -$310K 0.2% 24
2022
Q1 		$660K Sell
240,080
-61,899
-20% -$239K 0.43% 28
2021
Q4 		$1.91M Buy
+301,979
New +$2.94M 1.14% 23

Other funds holding CGTX

PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 20.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's CGTX Position: Q3 2022 in Review

Prosight Management sold out of Cognition Therapeutics (CGTX) in Q3 2022, closing a stake of 120,198 shares — an estimated $254K sold.

Prosight Management first reported a position in CGTX in Q4 2021 and held it in 3 quarters. The position peaked at $1.91M in Q4 2021. 31 funds tracked by Wall St. Rank hold CGTX as of Q3 2022.

  • Prosight Management reported no remaining Cognition Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prosight Management sold 120,198 Cognition Therapeutics shares in Q3 2022, an estimated $254K.
  • Prosight Management first reported a position in Cognition Therapeutics in Q4 2021 and held it in 3 quarters.
  • Prosight Management's Cognition Therapeutics position peaked at $1.91M in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2022.

Based on Prosight Management's 13F filing for Q3 2022, filed 14 Nov 2022.